2015 American Transplant Congress
Elevated Cancer Risk Among US Pediatric Solid Organ Transplant Recipients
Among pediatric transplant recipients, the effects of transplantation and immunosuppression on cancer risk may be unique from those observed in the adult transplant population. No…2015 American Transplant Congress
Interim Safety Experience in Transplant Patients Treated With Belatacept (Nulojix) in the Post-Approval Setting
Bristol-Myers Squibb Company, Princeton, NJ.
Purpose: Belatacept is a selective T-cell costimulation blocker indicated for prophylaxis of organ rejection in adult patients receiving a kidney transplant in combination with basiliximab…2015 American Transplant Congress
Temporal Increase in the Incidence of Post-Transplantation Lymphoproliferative Disorder in Adult Renal Transplant Recipients: Analysis of 2 US Insurance Administrative Claims Databases
Bristol-Myers Squibb Company, Princeton, NJ.
Purpose: Post-transplant lymphoproliferative disorder (PTLD) is a serious complication after kidney transplant. In a prior analysis using Medicare claims database from 1995 to 2003, the…2015 American Transplant Congress
Preemptive Rituximab Therapy of Epstein-Barr Virus (EBV) Infection to Prevent Post-Transplant Lymphoproliferative Disease (PTLD) After Pediatric Solid Organ Transplantation (SOT)
Purpose: More than 90% of pediatric PTLD after solid organ transplantation is associated with EBV infection. Reduction in immunosuppression is the first step to prevent…2015 American Transplant Congress
Identification of CXCR5+EBV-Specific CD8+ T Cells in Peripheral Blood of Pediatric Heart Transplant Recipients Correlates With IL-21 Production and EBV Reactivation
Approximately 70% of EBV asymptomatic pediatric heart transplant (HTx) recipients carry chronic EBV loads in peripheral blood. These EBV loads may occur due to impaired…2015 American Transplant Congress
IL-2-Dependent Natural Killer Cell Responses to Epstein-Barr Virus B Cell Lymphomas Involve the NKG2A/NKG2C Axis
Stanford University School of Medicine, Stanford, CA.
Epstein Barr virus (EBV) infection elicits a strong host immune response that is considered to be essential for control of the virus and for preventing…2015 American Transplant Congress
The Role of Antiviral Prophylaxis for the Prevention of Epstein-Barr Virus (EBV) Associated Post-Transplant Lymphoproliferative Disease (PTLD) in Solid Organ Transplant Recipients: A Systematic Review
Background The role of antiviral prophylaxis in EBV seronegative solid organ transplant recipients receiving organs from seropositive donors for prevention of PTLD remains controversial. We…2015 American Transplant Congress
Steroid Free Immunosuppression Protocol in Pediatric Kidney Transplant Recipients Using Alemtuzumab: A Retrospective Single Center Study
Background: Steroid free immunosuppression is attractive in pediatric kidney transplantation (KTx). Aim of the present study is to examine the patient survival, graft survival, rate…2015 American Transplant Congress
Clinical and Virologic Outcomes in High-Risk Adult EBV D+/R- Organ Transplant Recipients
Background:EBV D+/R- organ transplant recipients are a high risk group for developing PTLD. This subgroup of patients has been primarily evaluated in pediatric populations with…2015 American Transplant Congress
Epstein Barr Virus Modulates Host Cell MicroRNA-194 to Promote IL-10 Production in B Cell Lymphomas
Surgery/Division of Abdominal Transplant, Stanford University School of Medicine, Stanford, CA.
Epstein Barr virus (EBV) infection is associated with the development of post-transplant lymphoproliferative disorder (PTLD) which can manifest as aggressive B cell lymphomas in transplant…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- Next Page »